AbbVie Updates Q2, Full Year Guidance
() -- AbbVie (ABBV) said late Monday it expects Q2 results to include acquired in-process research and development and milestone expense of $291 million before tax, an impact of $0.17 to both GAAP and non-GAAP EPS. For 2026, AbbVie said it now expects adjusted EPS $13.91 to $14.11, including the Q2 impact of IPR&D and